Committed to transforming
the treatment of severe, chronic
autoimmune diseases.

Committed to transforming
the treatment of severe, chronic
autoimmune diseases.

News

2021-06-24
Imcyse appoints new Scientific Advisory Board and opens new laboratories for next phase of growth
2021-06-24
INNODIA is ready for a new phase – clinical trials
2021-02-17
Imcyse Raises Additional EUR 21.3 Million in Series B Financing Round – Pfizer Joins as Newest Shareholder
2021-02-03
Imcyse Enters into Research Collaboration and License Agreement for its Imotope™ Technology with Pfizer in Rheumatoid Arthritis
2021-02-03
Imcyse Announces Start of Phase 1b/2a IMPACT Study in Patients with Recent Onset Type 1 Diabetes

©imcyse 2023